Prevalence of Glaucoma in Belgium: a Multicenter National Trial (BelGlaucoma)
Primary Purpose
Glaucoma
Status
Completed
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
AI algorithm for the detection of glaucoma
Sponsored by
About this trial
This is an interventional screening trial for Glaucoma
Eligibility Criteria
Inclusion Criteria: Aged 40 years or above Exclusion Criteria: Aged under 40 years Insufficient knowledge of Dutch, French or English required to complete the imaging protocol and questionnaire Physical or mental inability to participate
Sites / Locations
- UZA
- Saint-Luc (UCL)
- Hôpital Erasme
- CHU Liège
- AZ Sint-Lucas
- UZ Leuven
- AZ Sint-Jan
- ZNA Middelheim
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Subjects
Arm Description
A fundus picture will be acquired without pupil dilation. This examination will be followed by an intra-ocular pressure measurement. The results will be discussed with the participating subject by the present physician. For each subject, both eyes will be evaluated. In case of suspected glaucoma, the subject will be referred to an ophthalmologist for further evaluation.
Outcomes
Primary Outcome Measures
Prevalence of glaucoma in Belgium
To study the prevalence of glaucoma in the Belgian population over 40 years old
Secondary Outcome Measures
Validation of AI algorithm
To validate an existing AI-based algorithm for automatic detection of glaucoma
Full Information
NCT ID
NCT05703724
First Posted
January 19, 2023
Last Updated
May 26, 2023
Sponsor
Universitaire Ziekenhuizen KU Leuven
Collaborators
Santen Oy
1. Study Identification
Unique Protocol Identification Number
NCT05703724
Brief Title
Prevalence of Glaucoma in Belgium: a Multicenter National Trial
Acronym
BelGlaucoma
Official Title
Prevalence of Glaucoma in Belgium: a Multicenter National Trial
Study Type
Interventional
2. Study Status
Record Verification Date
January 2023
Overall Recruitment Status
Completed
Study Start Date
March 8, 2023 (Actual)
Primary Completion Date
May 8, 2023 (Actual)
Study Completion Date
May 8, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Universitaire Ziekenhuizen KU Leuven
Collaborators
Santen Oy
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
To screen for the presence of glaucoma in a Belgian population over 40 years old using an AI algorithm developed for the detection of glaucoma based on fundus pictures.
Detailed Description
In this study, we aim to detect individuals with glaucoma and refer them for further evaluation and treatment when necessary. In so doing, we want to get an estimation of the prevalence of glaucoma in the Belgian population of 40+ years.
A fundus picture will be acquired without pupil dilation. This examination will be followed by an intra-ocular pressure measurement. The results will be discussed with the participating subject by the present physician. For each subject, both eyes will be evaluated. In case of suspected glaucoma, the subject will be referred to an ophthalmologist for further evaluation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glaucoma
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
1418 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Subjects
Arm Type
Other
Arm Description
A fundus picture will be acquired without pupil dilation. This examination will be followed by an intra-ocular pressure measurement. The results will be discussed with the participating subject by the present physician. For each subject, both eyes will be evaluated. In case of suspected glaucoma, the subject will be referred to an ophthalmologist for further evaluation.
Intervention Type
Device
Intervention Name(s)
AI algorithm for the detection of glaucoma
Intervention Description
The investigational device that will be used during this study is an AI algorithm embedded into an API for the detection of glaucoma developed by MONA.health
Primary Outcome Measure Information:
Title
Prevalence of glaucoma in Belgium
Description
To study the prevalence of glaucoma in the Belgian population over 40 years old
Time Frame
4 months
Secondary Outcome Measure Information:
Title
Validation of AI algorithm
Description
To validate an existing AI-based algorithm for automatic detection of glaucoma
Time Frame
7 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Aged 40 years or above
Exclusion Criteria:
Aged under 40 years
Insufficient knowledge of Dutch, French or English required to complete the imaging protocol and questionnaire
Physical or mental inability to participate
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ingeborg Stalmans, MD, PhD
Organizational Affiliation
Universitaire Ziekenhuizen KU Leuven
Official's Role
Study Chair
Facility Information:
Facility Name
UZA
City
Edegem
State/Province
Antwerpen
ZIP/Postal Code
2650
Country
Belgium
Facility Name
Saint-Luc (UCL)
City
Brussel
State/Province
Brussels Hoofdstedelijk Gewest
ZIP/Postal Code
1020
Country
Belgium
Facility Name
Hôpital Erasme
City
Brussel
State/Province
Brussels Hoofdstedelijk Gewest
ZIP/Postal Code
1070
Country
Belgium
Facility Name
CHU Liège
City
Liège
State/Province
Luik
ZIP/Postal Code
4000
Country
Belgium
Facility Name
AZ Sint-Lucas
City
Gent
State/Province
Oost-Vlaanderen
ZIP/Postal Code
9000
Country
Belgium
Facility Name
UZ Leuven
City
Leuven
State/Province
Vlaams-Brabant
ZIP/Postal Code
3000
Country
Belgium
Facility Name
AZ Sint-Jan
City
Brugge
State/Province
West-Vlaanderen
ZIP/Postal Code
8000
Country
Belgium
Facility Name
ZNA Middelheim
City
Antwerpen
ZIP/Postal Code
2020
Country
Belgium
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Prevalence of Glaucoma in Belgium: a Multicenter National Trial
We'll reach out to this number within 24 hrs